# Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

> **NCT03364231** · PHASE2 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia
- Non Follicular Indolent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Umbralisib

## Key facts

- **NCT ID:** NCT03364231
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364231, "Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03364231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*